Bone mineral density screening in patients receiving glucocorticoid therapy Glucocorticoids, Bone mineral density, FRAX score, Vertebral fracture assessment
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 20 years or older 2. Currently receiving at least 2.5 mg/day of prednisolone or at least 0.4 mg/day of dexamethasone 3. Receiving prednisolone or dexamethasone continuously for more than 3 months 4. No prior bone mineral density (BMD) assessment 5. No history of osteoporosis treatment (e.g., bisphosphonates, denosumab, calcitonin, or teriparatide)
Exclusion criteria
Exclusion criteria: 1. Prior diagnosis of osteoporosis 2. Pregnancy or breastfeeding 3. Diagnosis of bone cancer or metabolic bone disease 4. Presence of severe comorbid conditions or bedridden status 5. Chronic kidney disease stage 4 or above, or contraindication to osteoporosis medications 6. History of adverse effects or intolerance to osteoporosis treatment 7. Previous referral for or history of bone mineral density testing performed at other hospitals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of bone mineral density screening with in 6 months after the first alert the patient scheduled for bone mineral density testing | — |
Secondary
| Measure | Time frame |
|---|---|
| FRAX score assessment every visit FRAX score is a tool used to estimate a person 10-year probability of a major osteoporotic fracture. Note the result in the OPD card,Vertebral assessment every visit plain film spine,Calcium and vitamin D supplement every visit prescribed calcium and vitamin D supplement,Fracture incident every visit X-ray | — |
Countries
Thailand
Contacts
Phramongkutklao Hospital